Samjin Pharmaceutical Signs Joint Research Agreement with Quantum Mechanics-Based AI Drug Development Company 'Incelibro'

Lee Soo-min, Head of Samjin Pharmaceutical Research Center (left), and Cho Eun-seong, CEO of Incelibro, are signing a joint research agreement and posing for a commemorative photo.

[Asia Economy Reporter Lee Gwan-joo] Samjin Pharmaceutical announced on the 26th that it has signed a contract for joint AI drug development research with 'Inselibro,' a domestic artificial intelligence (AI) new drug development company based on quantum mechanics technology.

Through this contract, Inselibro will propose candidate substances derived using its AI platform to Samjin Pharmaceutical and take charge of optimizing the candidate substances. Samjin Pharmaceutical will synthesize the proposed new drug candidate substances, conduct efficacy evaluations and clinical development, and carry out the necessary procedures for verification and commercialization.

Inselibro's AI platform is based on 'quantum mechanics calculation technology,' which differs from existing AI new drug development companies. It is evaluated as a proprietary new drug development platform (MIND) that enhances the drug affinity and hit rate of candidate substances.

Lee Soo-min, head of the research center at Samjin Pharmaceutical, said, “New drug development using AI technology is an unstoppable global trend,” adding, “With the signing of this joint research contract, we will devote ourselves to integrating over 30 years of accumulated research and development know-how and cutting-edge infrastructure with AI platform technology to increase the possibility of developing innovative new drugs.”

This content was produced with the assistance of AI translation services.